Cancer Explained

Cancer
Field:Oncology
Synonyms:Malignant tumor, malignant neoplasm
Symptoms:Lump, abnormal bleeding, prolonged cough, unexplained weight loss, change in bowel movements
Risks:Exposure to carcinogens, tobacco, obesity, poor diet, lack of physical activity, excessive alcohol, certain infections
Treatment:Radiation therapy, surgery, chemotherapy, targeted therapy
Prognosis:Average five-year survival 66% (USA)
Frequency:24 million annually (2019)[1]
Deaths:10 million annually (2019)

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements.[2] While these symptoms may indicate cancer, they can also have other causes.[2] Over 100 types of cancers affect humans. Tobacco use is the cause of about 22% of cancer deaths.[3] Another 10% are due to obesity, poor diet, lack of physical activity or excessive alcohol consumption.[3] [4] [5] Other factors include certain infections, exposure to ionizing radiation, and environmental pollutants.[6] Infection with specific viruses, bacteria and parasites is an environmental factor causing approximately 16–18% of cancers worldwide.[7] These infectious agents include Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus infection, Epstein–Barr virus, Human T-lymphotropic virus 1, Kaposi's sarcoma-associated herpesvirus and Merkel cell polyomavirus. Human immunodeficiency virus (HIV) does not directly cause cancer but it causes immune deficiency that can magnify the risk due to other infections, sometimes up to several thousandfold (in the case of Kaposi's sarcoma). Importantly, vaccination against hepatitis B and human papillomavirus have been shown to nearly eliminate risk of cancers caused by these viruses in persons successfully vaccinated prior to infection.

These environmental factors act, at least partly, by changing the genes of a cell. Typically, many genetic changes are required before cancer develops. Approximately 5–10% of cancers are due to inherited genetic defects.[8] Cancer can be detected by certain signs and symptoms or screening tests.[3] It is then typically further investigated by medical imaging and confirmed by biopsy.[9] The risk of developing certain cancers can be reduced by not smoking, maintaining a healthy weight, limiting alcohol intake, eating plenty of vegetables, fruits, and whole grains, vaccination against certain infectious diseases, limiting consumption of processed meat and red meat, and limiting exposure to direct sunlight.[10] [11] Early detection through screening is useful for cervical and colorectal cancer.[12] The benefits of screening for breast cancer are controversial.[12] [13] Cancer is often treated with some combination of radiation therapy, surgery, chemotherapy and targeted therapy.[3] [14] Pain and symptom management are an important part of care.[3] Palliative care is particularly important in people with advanced disease.[3] The chance of survival depends on the type of cancer and extent of disease at the start of treatment.[12] In children under 15 at diagnosis, the five-year survival rate in the developed world is on average 80%.[15] For cancer in the United States, the average five-year survival rate is 66% for all ages.[16]

In 2015, about 90.5 million people worldwide had cancer.[17] In 2019, annual cancer cases grew by 23.6 million people, and there were 10 million deaths worldwide, representing over the previous decade increases of 26% and 21%, respectively.[18]

The most common types of cancer in males are lung cancer, prostate cancer, colorectal cancer, and stomach cancer.[19] [20] In females, the most common types are breast cancer, colorectal cancer, lung cancer, and cervical cancer.[12] [20] If skin cancer other than melanoma were included in total new cancer cases each year, it would account for around 40% of cases.[21] [22] In children, acute lymphoblastic leukemia and brain tumors are most common, except in Africa, where non-Hodgkin lymphoma occurs more often.[15] In 2012, about 165,000 children under 15 years of age were diagnosed with cancer.[19] The risk of cancer increases significantly with age, and many cancers occur more commonly in developed countries.[12] Rates are increasing as more people live to an old age and as lifestyle changes occur in the developing world.[23] The global total economic costs of cancer were estimated at US$1.16 trillion (equivalent to $ trillion in) per year .[24]

Etymology and definitions

The word comes from the ancient Greek καρκίνος, meaning 'crab' and 'tumor'. Greek physicians Hippocrates and Galen, among others, noted the similarity of crabs to some tumors with swollen veins. The word was introduced in English in the modern medical sense around 1600.[25]

Cancers comprise a large family of diseases that involve abnormal cell growth with the potential to invade or spread to other parts of the body.[3] They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often form a mass or lump, but may be distributed diffusely.[26] [27] All tumor cells show the six hallmarks of cancer. These characteristics are required to produce a malignant tumor. They include:

The progression from normal cells to cells that can form a detectable mass to cancer involves multiple steps known as malignant progression.[28] [29]

Signs and symptoms

See main article: Signs and symptoms of cancer.

When cancer begins, it produces no symptoms. Signs and symptoms appear as the mass grows or ulcerates. The findings that result depend on cancer's type and location. Few symptoms are specific. Many frequently occur in individuals who have other conditions. Cancer can be difficult to diagnose and can be considered a "great imitator".

People may become anxious or depressed post-diagnosis. The risk of suicide in people with cancer is approximately double.[30]

Local symptoms

Local symptoms may occur due to the mass of the tumor or its ulceration. For example, mass effects from lung cancer can block the bronchus resulting in cough or pneumonia; esophageal cancer can cause narrowing of the esophagus, making it difficult or painful to swallow; and colorectal cancer may lead to narrowing or blockages in the bowel, affecting bowel habits. Masses in breasts or testicles may produce observable lumps. Ulceration can cause bleeding that can lead to symptoms such as coughing up blood (lung cancer), anemia or rectal bleeding (colon cancer), blood in the urine (bladder cancer), or abnormal vaginal bleeding (endometrial or cervical cancer). Although localized pain may occur in advanced cancer, the initial tumor is usually painless. Some cancers can cause a buildup of fluid within the chest or abdomen.[31]

Systemic symptoms

Systemic symptoms may occur due to the body's response to the cancer. This may include fatigue, unintentional weight loss, or skin changes.[32] Some cancers can cause a systemic inflammatory state that leads to ongoing muscle loss and weakness, known as cachexia.[33]

Some cancers, such as Hodgkin's disease, leukemias, and liver or kidney cancers, can cause a persistent fever.[31]

Shortness of breath, called dyspnea, is a common symptom of cancer and its treatment. The causes of cancer-related dyspnea can include tumors in or around the lung, blocked airways, fluid in the lungs, pneumonia, or treatment reactions including an allergic response.[34] Treatment for dyspnea in patients with advanced cancer can include fans, bilevel ventilation, acupressure/reflexology and multicomponent nonpharmacological interventions.[35]

Some systemic symptoms of cancer are caused by hormones or other molecules produced by the tumor, known as paraneoplastic syndromes. Common paraneoplastic syndromes include hypercalcemia, which can cause altered mental state, constipation and dehydration, or hyponatremia, which can also cause altered mental status, vomiting, headaches, or seizures.[36]

Metastasis

See main article: Metastasis. Metastasis is the spread of cancer to other locations in the body. The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can metastasize. Most cancer deaths are due to cancer that has metastasized.[37]

Metastasis is common in the late stages of cancer and it can occur via the blood or the lymphatic system or both. The typical steps in metastasis are:

  1. Local invasion
  2. Intravasation into the blood or lymph.
  3. Circulation through the body.
  4. Extravasation into the new tissue.
  5. Proliferation
  6. Angiogenesis

Different types of cancers tend to metastasize to particular organs. Overall, the most common places for metastases to occur are the lungs, liver, brain, and the bones.[38]

While some cancers can be cured if detected early, metastatic cancer is more difficult to treat and control. Nevertheless, some recent treatments are demonstrating encouraging results.[39]

Causes

See main article: Causes of cancer. The majority of cancers, some 90–95% of cases, are due to genetic mutations from environmental and lifestyle factors.[6] The remaining 5–10% are due to inherited genetics.[6] Environmental refers to any cause that is not inherited, such as lifestyle, economic, and behavioral factors and not merely pollution.[40] Common environmental factors that contribute to cancer death include tobacco use (25–30%), diet and obesity (30–35%), infections (15–20%), radiation (both ionizing and non-ionizing, up to 10%), lack of physical activity, and pollution.[6] [41] Psychological stress does not appear to be a risk factor for the onset of cancer,[42] [43] though it may worsen outcomes in those who already have cancer.[42]

Environmental or lifestyle factors that caused cancer to develop in an individual can be identified by analyzing mutational signatures from genomic sequencing of tumor DNA. For example, this can reveal if lung cancer was caused by tobacco smoke, if skin cancer was caused by UV radiation, or if secondary cancers were caused by previous chemotherapy treatment.[44]

Cancer is generally not a transmissible disease.[45] Exceptions include rare transmissions that occur with pregnancies and occasional organ donors. However, transmissible infectious diseases such as hepatitis B, Epstein-Barr virus, Human Papilloma Virus and HIV, can contribute to the development of cancer.

Chemicals

Exposure to particular substances have been linked to specific types of cancer. These substances are called carcinogens.

Tobacco smoke, for example, causes 90% of lung cancer.[46] Tobacco use can cause cancer throughout the body including in the mouth and throat, larynx, esophagus, stomach, bladder, kidney, cervix, colon/rectum, liver and pancreas.[47] [48] Tobacco smoke contains over fifty known carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons.

Tobacco is responsible for about one in five cancer deaths worldwide[49] and about one in three in the developed world.[50] Lung cancer death rates in the United States have mirrored smoking patterns, with increases in smoking followed by dramatic increases in lung cancer death rates and, more recently, decreases in smoking rates since the 1950s followed by decreases in lung cancer death rates in men since 1990.[51] [52]

Alcohol increases the risk of cancer of the breast (in women), throat, liver, oesophagus, mouth, larynx, and colon.[53] In Western Europe, 10% of cancers in males and 3% of cancers in females are attributed to alcohol exposure, especially liver and digestive tract cancers.[54] Cancer from work-related substance exposures may cause between 2 and 20% of cases,[55] causing at least 200,000 deaths.[56] Cancers such as lung cancer and mesothelioma can come from inhaling tobacco smoke or asbestos fibers, or leukemia from exposure to benzene.[56]

Exposure to perfluorooctanoic acid (PFOA), which is predominantly used in the production of Teflon, is known to cause two kinds of cancer.[57] [58]

Chemotherapy drugs such as platinum-based compounds are carcinogens that increase the risk of secondary cancers[44]

Azathioprine, an immunosuppressive medication, is a carcinogen that can cause primary tumors to develop.[44]

Diet and exercise

See main article: Diet and cancer. Diet, physical inactivity, and obesity are related to up to 30–35% of cancer deaths.[6] [59]

Notes and References

  1. Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, etal . Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019 . JAMA Oncology . 8 . 3 . 420–444 . March 2022 . 34967848 . 8719276 . 10.1001/jamaoncol.2021.6987 . 2374-2437.
  2. Web site: Cancer – Signs and symptoms . NHS Choices . 10 June 2014 . live . https://web.archive.org/web/20140608104550/http://www.nhs.uk/Conditions/cancer/Pages/symptoms.aspx . 8 June 2014.
  3. Web site: Cancer . World Health Organization . 19 December 2018 . 12 September 2018.
  4. Web site: Obesity and Cancer Risk . National Cancer Institute . 4 July 2015 . 3 January 2012 . live . https://web.archive.org/web/20150704154440/http://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet#q3 . 4 July 2015.
  5. Jayasekara H, MacInnis RJ, Room R, English DR . Long-Term Alcohol Consumption and Breast, Upper Aero-Digestive Tract and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis . Alcohol and Alcoholism . 51 . 3 . 315–30 . May 2016 . 26400678 . 10.1093/alcalc/agv110 . free .
  6. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB . September 2008 . Cancer is a preventable disease that requires major lifestyle changes . Pharmaceutical Research . 25 . 9 . 2097–116 . 10.1007/s11095-008-9661-9 . 2515569 . 18626751.
  7. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Catherine. de Martel. Damien. Georges. Freddie. Bray. Jacques. Ferlay. Gary M. Clifford. 15 February 2020. The Lancet Global Health. 8. 2. e180–e190. 10.1016/S2214-109X(19)30488-7. 31862245 . free.
  8. Web site: . Heredity and Cancer . 22 July 2013 . live . https://web.archive.org/web/20130802043732/http://www.cancer.org/cancer/cancercauses/geneticsandcancer/heredity-and-cancer . 2 August 2013.
  9. Web site: How is cancer diagnosed? . American Cancer Society . 29 January 2013 . 10 June 2014 . live . https://web.archive.org/web/20140714120018/http://www.cancer.org/treatment/understandingyourdiagnosis/examsandtestdescriptions/testingbiopsyandcytologyspecimensforcancer/testing-biopsy-and-cytology-specimens-for-cancer-how-is-cancer-diagnosed . 14 July 2014.
  10. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T . 2067308 . American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity . CA: A Cancer Journal for Clinicians . 62 . 1 . 30–67 . 2012 . 22237782 . 10.3322/caac.20140. free .
  11. Parkin DM, Boyd L, Walker LC . 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010 . British Journal of Cancer . 105 . Suppl 2 . S77–81 . December 2011 . 22158327 . 3252065 . 10.1038/bjc.2011.489.
  12. Book: World Cancer Report 2014 . 2014 . World Health Organization . 978-92-832-0429-9 . Chapter 4.7 . https://web.archive.org/web/20170712114430/http://www.searo.who.int/publications/bookstore/documents/9283204298/en/ . 12 July 2017 .
  13. Gøtzsche PC, Jørgensen KJ . Screening for breast cancer with mammography . The Cochrane Database of Systematic Reviews . 2013 . 6 . CD001877 . June 2013 . 23737396 . 6464778 . 10.1002/14651858.CD001877.pub5.
  14. Web site: Targeted Cancer Therapies . cancer.gov . National Cancer Institute . 26 February 2018 . 28 March 2018 .
  15. Book: World Cancer Report 2014 . 2014 . World Health Organization . 978-92-832-0429-9 . Chapter 1.3 . https://web.archive.org/web/20170712114430/http://www.searo.who.int/publications/bookstore/documents/9283204298/en/ . 12 July 2017 .
  16. Web site: SEER Stat Fact Sheets: All Cancer Sites . National Cancer Institute . 18 June 2014 . live . https://web.archive.org/web/20100926191037/http://seer.cancer.gov/statfacts/html/all.html . 26 September 2010.
  17. GBD . Global Burden of Disease Study . Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 . The Lancet . 8 October 2016 . 388 . 10053 . 1545–1602 . 27733282 . 10.1016/S0140-6736(16)31678-6 . 5055577.
  18. 10.1146/annurev-cancerbio-030419-033612. free. Metabolic Drivers in Hereditary Cancer Syndromes. 2020. Sciacovelli M, Schmidt C, Maher ER, Frezza C . Annual Review of Cancer Biology. 4. 77–97.
  19. Book: World Cancer Report 2014 . 2014 . World Health Organization . 978-92-832-0429-9 . Chapter 1.1.
  20. Siegel RL, Miller KD, Wagle NS, Jemal A . Cancer statistics, 2023 . CA . 73 . 1 . 17–48 . January 2023 . 36633525 . 10.3322/caac.21763 . free .
  21. Dubas LE, Ingraffea A . Nonmelanoma skin cancer . Facial Plastic Surgery Clinics of North America . 21 . 1 . 43–53 . February 2013 . 23369588 . 10.1016/j.fsc.2012.10.003 .
  22. Cakir BÖ, Adamson P, Cingi C . Epidemiology and economic burden of nonmelanoma skin cancer . Facial Plastic Surgery Clinics of North America . 20 . 4 . 419–422 . November 2012 . 23084294 . 10.1016/j.fsc.2012.07.004 .
  23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics . CA . 61 . 2 . 69–90 . February 2011 . 21296855 . 10.3322/caac.20107 . 30500384 . free .
  24. Book: World Report 2014 . 2014 . World Health Organization . 978-92-832-0429-9 . Chapter 6.7 . https://web.archive.org/web/20170712114430/http://www.searo.who.int/publications/bookstore/documents/9283204298/en/ . 12 July 2017 .
  25. Web site: cancer . live . https://web.archive.org/web/20221107103233/https://www.etymonline.com/word/cancer . 7 November 2022 . www.etymonline.com.
  26. Web site: Cancer Glossary . cancer.org . American Cancer Society . 11 September 2013 . live . https://web.archive.org/web/20130901160014/http://www.cancer.org/cancer/cancerglossary/index . 1 September 2013.
  27. Web site: What is cancer? . cancer.gov . National Cancer Institute . 28 March 2018 . 17 September 2007.
  28. Hanahan D, Weinberg RA . 1478778 . The hallmarks of cancer . Cell . 100 . 1 . 57–70 . January 2000 . 10647931 . 10.1016/S0092-8674(00)81683-9 . Douglas Hanahan . Robert Weinberg (biologist). free .
  29. Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation . Cell . 144 . 5 . 646–74 . March 2011 . 21376230 . 10.1016/j.cell.2011.02.013. free .
  30. Anguiano L, Mayer DK, Piven ML, Rosenstein D . 45874503 . A literature review of suicide in cancer patients . Cancer Nursing . 35 . 4 . E14–26 . July–August 2012 . 21946906 . 10.1097/NCC.0b013e31822fc76c. free .
  31. Holland Chp. 1
  32. Book: O'Dell M, Stubblefield M . [{{google books |plainurl=y |id=_JaPlNYgXkEC |page=983}} Cancer rehabilitation principles and practice ]. 2009 . Demos Medical . New York . 978-1-933864-33-4 . 983 .
  33. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE . Definition and classification of cancer cachexia: an international consensus . The Lancet. Oncology . 12 . 5 . 489–95 . May 2011 . 21296615 . 10.1016/S1470-2045(10)70218-7 .
  34. Web site: Shortness of Breath Cancer-related Side Effects . 10 October 2023 . www.cancer.org . en.
  35. Book: Dy SM, Gupta A, Waldfogel JM, Sharma R, Zhang A, Feliciano JL, Sedhom R, Day J, Gersten RA, Davidson PM, Bass EB . Interventions for Breathlessness in Patients With Advanced Cancer . 2020 . Agency for Healthcare Research and Quality (US) . AHRQ Comparative Effectiveness Reviews . Rockville (MD) . 33289989.
  36. Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A . Paraneoplastic endocrine syndromes . Endocrine-Related Cancer . 24 . 6 . R173–R190 . June 2017 . 28341725 . 10.1530/ERC-17-0036 . free .
  37. Web site: What is Metastasized Cancer? . National Comprehensive Cancer Network . 18 July 2013 . https://web.archive.org/web/20130707200430/http://www.nccn.com/component/content/article/54-cancer-basics/925-what-is-metastasized-cancer.html . 7 July 2013.
  38. Web site: Metastatic Cancer: Questions and Answers . 28 March 2018. National Cancer Institute . 12 May 2015.
  39. Web site: Why is cancer so hard to cure? . 17 July 2023 . The Age. 15 July 2023 .
  40. Book: Manton K, Akushevich I, Kravchenko J . [{{google books |plainurl=y |id=fDIbuwtYPlAC}} Cancer Mortality and Morbidity Patterns in the U.S. Population: An Interdisciplinary Approach ]. 28 December 2008. Springer Science & Business Media. 978-0-387-78193-8. The term environment refers not only to air, water, and soil but also to substances and conditions at home and at the workplace, including diet, smoking, alcohol, drugs, exposure to chemicals, sunlight, ionizing radiation, electromagnetic fields, infectious agents, etc. Lifestyle, economic and behavioral factors are all aspects of our environment. .
  41. Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States . CA: A Cancer Journal for Clinicians . 68 . 1 . 31–54 . January 2018 . 29160902 . 10.3322/caac.21440 . free .
  42. Cohen S, Murphy ML, Prather AA . Ten Surprising Facts About Stressful Life Events and Disease Risk . Annual Review of Psychology . 70 . 577–597 . January 2019 . 29949726 . 6996482 . 10.1146/annurev-psych-010418-102857 . the strongest conclusion derived from decades of research on stressors and cancer is that stressful events may be associated with decreased cancer survival but are probably not associated with disease incidence (Chida et al. 2008). .
  43. Heikkilä K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, Bonenfant S, Borritz M, Bouillon K, Burr H, Dragano N, Geuskens GA, Goldberg M, Hamer M, Hooftman WE, Houtman IL, Joensuu M, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Madsen IE, Magnusson Hanson LL, Marmot MG, Nielsen ML, Nordin M, Oksanen T, Pentti J, Salo P, Rugulies R, Steptoe A, Suominen S, Vahtera J, Virtanen M, Väänänen A, Westerholm P, Westerlund H, Zins M, Ferrie JE, Singh-Manoux A, Batty GD, Kivimäki M . Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116,000 European men and women . BMJ . 346 . f165 . February 2013 . 23393080 . 3567204 . 10.1136/bmj.f165 .
  44. Steele CD, Pillay N, Alexandrov LB . An overview of mutational and copy number signatures in human cancer . The Journal of Pathology . 257 . 4 . 454–465 . July 2022 . 35420163 . 9324981 . 10.1002/path.5912 .
  45. Tolar J, Neglia JP . 34197973 . Transplacental and other routes of cancer transmission between individuals . Journal of Pediatric Hematology/Oncology . 25 . 6 . 430–4 . June 2003 . 12794519 . 10.1097/00043426-200306000-00002.
  46. Biesalski HK, Bueno de Mesquita B, Chesson A, Chytil F, Grimble R, Hermus RJ, Köhrle J, Lotan R, Norpoth K, Pastorino U, Thurnham D . European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel . CA: A Cancer Journal for Clinicians . 48 . 3 . 167–76; discussion 164–66 . 1998 . 9594919 . 10.3322/canjclin.48.3.167. 20891885 . free .
  47. Kuper H, Boffetta P, Adami HO . 6132726 . Tobacco use and cancer causation: association by tumour type . Journal of Internal Medicine . 252 . 3 . 206–24 . September 2002 . 12270001 . 10.1046/j.1365-2796.2002.01022.x. free .
  48. Web site: 27 August 2019 . Cancer and Tobacco Use . 25 October 2023 . Centers for Disease Control and Prevention . en-us.
  49. Kuper H, Adami HO, Boffetta P . 9172672 . Tobacco use, cancer causation and public health impact . Journal of Internal Medicine . 251 . 6 . 455–66 . June 2002 . 12028500 . 10.1046/j.1365-2796.2002.00993.x. free .
  50. Sasco AJ, Secretan MB, Straif K . Tobacco smoking and cancer: a brief review of recent epidemiological evidence . Lung Cancer . 45 . Suppl 2 . S3–9 . August 2004 . 15552776 . 10.1016/j.lungcan.2004.07.998.
  51. Thun MJ, Jemal A . How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? . Tobacco Control . 15 . 5 . 345–47 . October 2006 . 16998161 . 2563648 . 10.1136/tc.2006.017749.
  52. Dubey S, Powell CA . Update in lung cancer 2007 . American Journal of Respiratory and Critical Care Medicine . 177 . 9 . 941–46 . May 2008 . 18434333 . 2720127 . 10.1164/rccm.200801-107UP.
  53. News: US top doctor calls for cancer warnings on alcohol . BBC.
  54. Schütze M, Boeing H, Pischon T, Rehm J, Kehoe T, Gmel G, Olsen A, Tjønneland AM, Dahm CC, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Benetou V, Zylis D, Kaaks R, Rohrmann S, Palli D, Berrino F, Tumino R, Vineis P, Rodríguez L, Agudo A, Sánchez MJ, Dorronsoro M, Chirlaque MD, Barricarte A, Peeters PH, van Gils CH, Khaw KT, Wareham N, Allen NE, Key TJ, Boffetta P, Slimani N, Jenab M, Romaguera D, Wark PA, Riboli E, Bergmann MM . Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study . BMJ . 342 . d1584 . April 2011 . 21474525 . 3072472 . 10.1136/bmj.d1584.
  55. Irigaray P, Newby JA, Clapp R, Hardell L, Howard V, Montagnier L, Epstein S, Belpomme D . Lifestyle-related factors and environmental agents causing cancer: an overview . Biomedicine & Pharmacotherapy . 61 . 10 . 640–58 . December 2007 . 18055160 . 10.1016/j.biopha.2007.10.006.
  56. WHO calls for prevention of cancer through healthy workplaces . World Health Organization . 27 April 2007 . 13 October 2007 . https://web.archive.org/web/20071012202014/http://www.who.int/mediacentre/news/notes/2007/np19/en/index.html . 12 October 2007.
  57. Web site: Erin Brockovich Blasts U.S. Regulation of Toxic Chemicals . scientificamerican.com . Scientific American . 28 December 2020.
  58. News: Environmental Pollutant, PFOA, Associated with Increased Risk of Kidney Cancer . . 24 September 2020.
  59. Park S, Bae J, Nam BH, Yoo KY . Aetiology of cancer in Asia . Asian Pacific Journal of Cancer Prevention . 9 . 3 . 371–80 . 2008 . 18990005 . https://web.archive.org/web/20110904052252/http://www.apocpcontrol.org/page/popup_paper_file_view.php?pno=MzcxIFBhcmsucCZrY29kZT04MjI=&pgubun=i . 4 September 2011.
  60. Book: Brenner H, Rothenbacher D, Arndt V . Epidemiology of Stomach Cancer . Cancer Epidemiology . 472 . . 467–77 . 2009 . 19107449 . 10.1007/978-1-60327-492-0_23 . 978-1-60327-491-3 . Methods in Molecular Biology . 5450 . 2166976 .
  61. Buell P, Dunn JE . Cancer Mortality Among Japanese Issei and Nisei of California . Cancer . 18 . 5 . 656–64 . May 1965 . 14278899 . 10.1002/1097-0142(196505)18:5<656::AID-CNCR2820180515>3.0.CO;2-3. free .
  62. Moore PS, Chang Y . Why do viruses cause cancer? Highlights of the first century of human tumour virology . Nature Reviews. Cancer . 10 . 12 . 878–889 . December 2010 . 21102637 . 3718018 . 10.1038/nrc2961 . Springer Science and Business Media LLC .
  63. Pagano JS, Blaser M, Buendia MA, Damania B, Khalili K, Raab-Traub N, Roizman B . Infectious agents and cancer: criteria for a causal relation . Seminars in Cancer Biology . 14 . 6 . 453–71 . December 2004 . 15489139 . 10.1016/j.semcancer.2004.06.009 .
  64. Ljubojevic S, Skerlev M . HPV-associated diseases . Clinics in Dermatology . 32 . 2 . 227–34 . 2014 . 24559558 . 10.1016/j.clindermatol.2013.08.007.
  65. Samaras V, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME . Chronic bacterial and parasitic infections and cancer: a review . Journal of Infection in Developing Countries . 4 . 5 . 267–81 . June 2010 . 20539059 . 10.3855/jidc.819 . live . https://web.archive.org/web/20111004123357/http://www.jidc.org/index.php/journal/article/download/20539059/387 . 4 October 2011. free .
  66. Web site: Radiation . National Cancer Institute . 8 June 2019 . en . 29 April 2015.
  67. Web site: Sunlight . National Cancer Institute . 8 June 2019 . en . 29 April 2015.
  68. Web site: Cancer prevention . WHO . 8 June 2019.
  69. Book: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E . Cancer medicine . Little JB . Chapter 14: Ionizing Radiation . 6th . B.C. Decker . Hamilton, Ont . 2000 . 978-1-55009-113-7 . https://www.ncbi.nlm.nih.gov/books/NBK20793/ . live . https://web.archive.org/web/20160102193148/http://www.ncbi.nlm.nih.gov/books/NBK20793/ . 2 January 2016.
  70. Brenner DJ, Hall EJ . 2760372 . Computed tomography—an increasing source of radiation exposure . The New England Journal of Medicine . 357 . 22 . 2277–84 . November 2007 . 18046031 . 10.1056/NEJMra072149.
  71. Book: Cleaver JE, Mitchell DL . Bast RC, Kufe DW, Pollock RE . Holland-Frei Cancer Medicine . 5th . B.C. Decker . Hamilton, Ontario . 2000 . 15. Ultraviolet Radiation Carcinogenesis . 978-1-55009-113-7 . https://www.ncbi.nlm.nih.gov/books/NBK20854/ . 31 January 2011 . etal . live . https://web.archive.org/web/20150904102726/http://www.ncbi.nlm.nih.gov/books/NBK20854/ . 4 September 2015.
  72. Web site: IARC classifies radiofrequency electromagnetic fields as possibly carcinogenic to humans . World Health Organization . live . https://web.archive.org/web/20110601063650/http://www.iarc.fr/en/media-centre/pr/2011/pdfs/pr208_E.pdf . 1 June 2011.
  73. Web site: Electromagnetic Fields and Cancer . National Cancer Institute . 8 June 2019 . en . 7 January 2019.
  74. Web site: Cell Phones and Cancer Risk – National Cancer Institute . Cancer.gov . 8 May 2013 . 28 March 2018.
  75. Roukos DH . 24746283 . Genome-wide association studies: how predictable is a person's cancer risk? . Expert Review of Anticancer Therapy . 9 . 4 . 389–92 . April 2009 . 19374592 . 10.1586/era.09.12. free .
  76. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N . 25299272 . Colorectal cancer . Lancet . 375 . 9719 . 1030–47 . March 2010 . 20304247 . 10.1016/S0140-6736(10)60353-4.
  77. Kampman E . A first-degree relative with colorectal cancer: what are we missing? . Cancer Epidemiology, Biomarkers & Prevention . 16 . 1 . 1–3 . January 2007 . 17220324 . 10.1158/1055-9965.EPI-06-0984 . free .
  78. Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben KK, Andrew AS, Bencko V, Bickeböller H, Boffetta P, Brennan P, Brenner H, Duell EJ, Fabianova E, Field JK, Foretova L, Friis S, Harris CC, Holcatova I, Hong YC, Isla D, Janout V, Kiemeney LA, Kiyohara C, Lan Q, Lazarus P, Lissowska J, Le Marchand L, Mates D, Matsuo K, Mayordomo JI, McLaughlin JR, Morgenstern H, Müeller H, Orlow I, Park BJ, Pinchev M, Raji OY, Rennert HS, Rudnai P, Seow A, Stucker I, Szeszenia-Dabrowska N, Dawn Teare M, Tjønnelan A, Ugolini D, van der Heijden HF, Wichmann E, Wiencke JK, Woll PJ, Yang P, Zaridze D, Zhang ZF, Etzel CJ, Hung RJ . Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium . European Journal of Cancer . 48 . 13 . 1957–68 . September 2012 . 22436981 . 10.1016/j.ejca.2012.01.038 . 3445438 .
  79. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P . Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis . International Journal of Cancer . 107 . 5 . 797–803 . December 2003 . 14566830 . 10.1002/ijc.11466 . 25591527 .
  80. Singletary SE . Rating the risk factors for breast cancer . Annals of Surgery . 237 . 4 . 474–482 . April 2003 . 12677142 . 1514477 . 10.1097/01.SLA.0000059969.64262.87 .
  81. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V . Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk . The Lancet. Oncology . 12 . 8 . 785–94 . August 2011 . 21782509 . 3148429 . 10.1016/S1470-2045(11)70154-1 .
  82. Book: Maltoni CF, Holland JF . Bast RC, Kufe DW, Pollock RE . Holland-Frei Cancer Medicine . 5th . B.C. Decker . Hamilton, Ontario . 2000 . Chapter 16: Physical Carcinogens . 978-1-55009-113-7 . https://www.ncbi.nlm.nih.gov/books/NBK20770/ . 31 January 2011 . etal . live . https://web.archive.org/web/20150904102726/http://www.ncbi.nlm.nih.gov/books/NBK20770/ . 4 September 2015.
  83. Book: Gaeta JF . Bast RC, Kufe DW, Pollock RE . Holland-Frei Cancer Medicine . 5th . B.C. Decker . Hamilton, Ontario . 2000 . Chapter 17: Trauma and Inflammation . 978-1-55009-113-7 . https://www.ncbi.nlm.nih.gov/books/NBK20784/ . 27 January 2011. etal . live . https://web.archive.org/web/20150904102726/http://www.ncbi.nlm.nih.gov/books/NBK20784/ . 4 September 2015.
  84. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A . Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability . Carcinogenesis . 30 . 7 . 1073–81 . July 2009 . 19468060 . 10.1093/carcin/bgp127 . review. free .
  85. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R . Interaction of tumor cells with the microenvironment . Cell Communication and Signaling . 9 . 18 . September 2011 . 21914164 . 10.1186/1478-811X-9-18 . 18 . 3180438 . free .
  86. Mantovani A . Molecular pathways linking inflammation and cancer . Current Molecular Medicine . 10 . 4 . 369–73 . June 2010 . 20455855 . 10.2174/156652410791316968 . review.
  87. Borrello MG, Degl'Innocenti D, Pierotti MA . Inflammation and cancer: the oncogene-driven connection . Cancer Letters . 267 . 2 . 262–70 . August 2008 . 18502035 . 10.1016/j.canlet.2008.03.060 . review.
  88. Book: Henderson BE, Bernstein L, Ross RK . Bast RC, Kufe DW, Pollock RE . Holland-Frei Cancer Medicine . 5th . B.C. Decker . Hamilton, Ontario . 2000 . Chapter 13: Hormones and the Etiology of Cancer . 978-1-55009-113-7 . https://www.ncbi.nlm.nih.gov/books/NBK20759/ . 27 January 2011 . etal . live . https://web.archive.org/web/20170910174411/https://www.ncbi.nlm.nih.gov/books/NBK20759/ . 10 September 2017.
  89. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM . Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis . International Journal of Cancer . 124 . 10 . 2416–29 . May 2009 . 19142965 . 2743036 . 10.1002/ijc.24202.
  90. Han Y, Chen W, Li P, Ye J . Association Between Coeliac Disease and Risk of Any Malignancy and Gastrointestinal Malignancy: A Meta-Analysis . Medicine . 94 . 38 . e1612 . September 2015 . 26402826 . 4635766 . 10.1097/MD.0000000000001612.
  91. Axelrad JE, Lichtiger S, Yajnik V . Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment . World Journal of Gastroenterology . 22 . 20 . 4794–801 . May 2016 . 27239106 . 4873872 . 10.3748/wjg.v22.i20.4794 . free .
  92. Croce CM . 8813076 . Oncogenes and cancer . The New England Journal of Medicine . 358 . 5 . 502–11 . January 2008 . 18234754 . 10.1056/NEJMra072367.
  93. Knudson AG . 20201610 . Two genetic hits (more or less) to cancer . Nature Reviews. Cancer . 1 . 2 . 157–62 . November 2001 . 11905807 . 10.1038/35101031.
  94. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E . Hypoxia and defective apoptosis drive genomic instability and tumorigenesis . Genes & Development . 18 . 17 . 2095–107 . September 2004 . 15314031 . 515288 . 10.1101/gad.1204904.
  95. Merlo LM, Pepper JW, Reid BJ, Maley CC . 8040576 . Cancer as an evolutionary and ecological process . Nature Reviews. Cancer . 6 . 12 . 924–35 . December 2006 . 17109012 . 10.1038/nrc2013.
  96. Baylin SB, Ohm JE . 2514545 . Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? . Nature Reviews. Cancer . 6 . 2 . 107–16 . February 2006 . 16491070 . 10.1038/nrc1799.
  97. Kanwal R, Gupta S . Epigenetic modifications in cancer . Clinical Genetics . 81 . 4 . 303–11 . April 2012 . 22082348 . 3590802 . 10.1111/j.1399-0004.2011.01809.x.
  98. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce CM, Fusco A . Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma . Molecular and Cellular Biology . 23 . 7 . 2225–38 . April 2003 . 12640109 . 150734 . 10.1128/MCB.23.7.2225-2238.2003. /
  99. Schnekenburger M, Diederich M . Epigenetics Offer New Horizons for Colorectal Cancer Prevention . Current Colorectal Cancer Reports . 8 . 1 . 66–81 . March 2012 . 22389639 . 3277709 . 10.1007/s11888-011-0116-z.
  100. Jacinto FV, Esteller M . Mutator pathways unleashed by epigenetic silencing in human cancer . Mutagenesis . 22 . 4 . 247–53 . July 2007 . 17412712 . 10.1093/mutage/gem009. free .
  101. Lahtz C, Pfeifer GP . Epigenetic changes of DNA repair genes in cancer . Journal of Molecular Cell Biology . 3 . 1 . 51–8 . February 2011 . 21278452 . 3030973 . 10.1093/jmcb/mjq053.
  102. Bernstein C, Nfonsam V, Prasad AR, Bernstein H . Epigenetic field defects in progression to cancer . World Journal of Gastrointestinal Oncology . 5 . 3 . 43–49 . March 2013 . 23671730 . 3648662 . 10.4251/wjgo.v5.i3.43 . free .
  103. Narayanan L, Fritzell JA, Baker SM, Liskay RM, Glazer PM . Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2 . Proceedings of the National Academy of Sciences of the United States of America . 94 . 7 . 3122–27 . April 1997 . 9096356 . 20332 . 10.1073/pnas.94.7.3122. 1997PNAS...94.3122N . free .
  104. Hegan DC, Narayanan L, Jirik FR, Edelmann W, Liskay RM, Glazer PM . Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6 . Carcinogenesis . 27 . 12 . 2402–08 . December 2006 . 16728433 . 2612936 . 10.1093/carcin/bgl079.
  105. Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A . Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation . EMBO Reports . 3 . 3 . 255–60 . March 2002 . 11850397 . 1084010 . 10.1093/embo-reports/kvf037.
  106. German J . Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients . American Journal of Human Genetics . 21 . 2 . 196–227 . March 1969 . 5770175 . 1706430.
  107. O'Hagan HM, Mohammad HP, Baylin SB . Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island . PLOS Genetics . 4 . 8 . e1000155 . August 2008 . 18704159 . 2491723 . 10.1371/journal.pgen.1000155 . Lee JT . free .
  108. Cuozzo C, Porcellini A, Angrisano T, Morano A, Lee B, Di Pardo A, Messina S, Iuliano R, Fusco A, Santillo MR, Muller MT, Chiariotti L, Gottesman ME, Avvedimento EV . DNA damage, homology-directed repair, and DNA methylation . PLOS Genetics . 3 . 7 . e110 . July 2007 . 17616978 . 1913100 . 10.1371/journal.pgen.0030110 . free .
  109. Malkin D . Li-fraumeni syndrome . Genes & Cancer . 2 . 4 . 475–84 . April 2011 . 21779515 . 3135649 . 10.1177/1947601911413466.
  110. Fearon ER . Human cancer syndromes: clues to the origin and nature of cancer . Science . 278 . 5340 . 1043–50 . November 1997 . 9353177 . 10.1126/science.278.5340.1043. 1997Sci...278.1043F .
  111. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW . Cancer genome landscapes . Science . 339 . 6127 . 1546–58 . March 2013 . 23539594 . 3749880 . 10.1126/science.1235122. 2013Sci...339.1546V .
  112. Zheng J . Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review) . . 4 . 6 . 1151–1157 . 2012 . 10.3892/ol.2012.928 . 3506713 . 23226794.
  113. Seyfried TN, Shelton LM . Cancer as a metabolic disease . Nutrition & Metabolism . 7 . 7 . 2010 . 10.1186/1743-7075-7-7 . 2845135 . 20181022 . free .
  114. Weiss JM . The promise and peril of targeting cell metabolism for cancer therapy . . 69 . 2 . 255–261 . 2020 . 10.1007/s00262-019-02432-7 . 7004869 . 31781842.
  115. Farhadi P, Yarani R, Dokaneheifard S, Mansouri K . The emerging role of targeting cancer metabolism for cancer therapy . . 42 . 10 . 1010428320965284 . 2020 . 10.1177/1010428320965284 . 33028168 . 222214285 . free .
  116. Pavlova NN, Thompson CB . The Emerging Hallmarks of Cancer Metabolism . . 23 . 1 . 27–47 . 2016 . 10.1016/j.cmet.2015.12.006 . 4715268 . 26771115.
  117. Yadav UP, Singh T, Kumar P, Mehta K . Metabolic Adaptations in Cancer Stem Cells . . 10 . 1010 . 2020 . 10.3389/fonc.2020.01010 . 7330710 . 32670883. free .
  118. Web site: Cancer Screening Guidelines Detecting Cancer Early . 24 May 2022 . American Cancer Society. 14 March 2022 . en.
  119. Book: Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient . Connolly JL, Schnitt SJ, Wang HH, Longtine JA, Dvorak A, Dvorak HF . Harold F. Dvorak . Holland JF, Frei E, Kufe DW . James F. Holland . Emil Frei . Holland-Frei Cancer Medicine . 6 . Hamilton (ON) . BC Decker . 2003 . 978-1-55009-213-4 . https://www.ncbi.nlm.nih.gov/books/NBK13237/ .
  120. Galway K, Black A, Cantwell M, Cardwell CR, Mills M, Donnelly M . Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients . The Cochrane Database of Systematic Reviews . 11 . CD007064 . November 2012 . 11 . 23152241 . 6457819 . 10.1002/14651858.cd007064.pub2 .
  121. Pearson C . 10 January 2024 . Why Some People Keep Serious Illnesses Private . The New York Times.
  122. Book: Varricchio C . [{{google books |plainurl=y |id=jkqdgZcF9qcC |page=229}} A cancer source book for nurses ]. Jones and Bartlett Publishers . Boston . 2004 . 229 . 978-0-7637-3276-9 .
  123. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L,Underwood CI, Glass C . Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults,Lung – Small cell carcinoma. Lancet . 384 . 9945 . 755–65 . August 2014 . 25129328 . 10.1016/S0140-6736(14)60892-8 . 4151483/> Physical inactivity is believed to contribute to cancer risk, not only through its effect on body weight but also through negative effects on the immune system and endocrine system. More than half of the effect from the diet is due to overnutrition (eating too much), rather than from eating too few vegetables or other healthful foods.

    Some specific foods are linked to specific cancers. A high-salt diet is linked to gastric cancer. Aflatoxin B1, a frequent food contaminant, causes liver cancer. Betel nut chewing can cause oral cancer.[59] National differences in dietary practices may partly explain differences in cancer incidence. For example, gastric cancer is more common in Japan due to its high-salt diet[60] while colon cancer is more common in the United States. Immigrant cancer profiles mirror those of their new country, often within one generation.[61]

    Infection

    See main article: Infectious causes of cancer. Worldwide, approximately 18% of cancer deaths are related to infectious diseases. This proportion ranges from a high of 25% in Africa to less than 10% in the developed world. Viruses[62] are the usual infectious agents that cause cancer but bacteria and parasites may also play a role. Oncoviruses (viruses that can cause human cancer) include:

    Bacterial infection may also increase the risk of cancer, as seen in

    Parasitic infections associated with cancer include:

    Radiation

    See main article: Radiation-induced cancer. Radiation exposure such as ultraviolet radiation and radioactive material is a risk factor for cancer.[66] [67] [68] Many non-melanoma skin cancers are due to ultraviolet radiation, mostly from sunlight. Sources of ionizing radiation include medical imaging and radon gas.

    Ionizing radiation is not a particularly strong mutagen.[69] Residential exposure to radon gas, for example, has similar cancer risks as passive smoking. Radiation is a more potent source of cancer when combined with other cancer-causing agents, such as radon plus tobacco smoke. Radiation can cause cancer in most parts of the body, in all animals and at any age. Children are twice as likely to develop radiation-induced leukemia as adults; radiation exposure before birth has ten times the effect.

    Medical use of ionizing radiation is a small but growing source of radiation-induced cancers. Ionizing radiation may be used to treat other cancers, but this may, in some cases, induce a second form of cancer. It is also used in some kinds of medical imaging.[70]

    Prolonged exposure to ultraviolet radiation from the sun can lead to melanoma and other skin malignancies.[71] Clear evidence establishes ultraviolet radiation, especially the non-ionizing medium wave UVB, as the cause of most non-melanoma skin cancers, which are the most common forms of cancer in the world.

    Non-ionizing radio frequency radiation from mobile phones, electric power transmission and other similar sources has been described as a possible carcinogen by the World Health Organization's International Agency for Research on Cancer.[72] Evidence, however, has not supported a concern.[73] This includes that studies have not found a consistent link between mobile phone radiation and cancer risk.[74]

    Heredity

    See main article: Cancer syndrome. The vast majority of cancers are non-hereditary (sporadic). Hereditary cancers are primarily caused by an inherited genetic defect. Less than 0.3% of the population are carriers of a genetic mutation that has a large effect on cancer risk and these cause less than 3–10% of cancer.[75] Some of these syndromes include: certain inherited mutations in the genes BRCA1 and BRCA2 with a more than 75% risk of breast cancer and ovarian cancer, and hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome), which is present in about 3% of people with colorectal cancer,[76] among others.

    Statistically for cancers causing most mortality, the relative risk of developing colorectal cancer when a first-degree relative (parent, sibling or child) has been diagnosed with it is about 2.[77] The corresponding relative risk is 1.5 for lung cancer,[78] and 1.9 for prostate cancer.[79] For breast cancer, the relative risk is 1.8 with a first-degree relative having developed it at 50 years of age or older, and 3.3 when the relative developed it when being younger than 50 years of age.[80]

    Taller people have an increased risk of cancer because they have more cells than shorter people. Since height is genetically determined to a large extent, taller people have a heritable increase of cancer risk.[81]

    Physical agents

    Some substances cause cancer primarily through their physical, rather than chemical, effects.[82] A prominent example of this is prolonged exposure to asbestos, naturally occurring mineral fibers that are a major cause of mesothelioma (cancer of the serous membrane) usually the serous membrane surrounding the lungs. Other substances in this category, including both naturally occurring and synthetic asbestos-like fibers, such as wollastonite, attapulgite, glass wool and rock wool, are believed to have similar effects. Non-fibrous particulate materials that cause cancer include powdered metallic cobalt and nickel and crystalline silica (quartz, cristobalite and tridymite). Usually, physical carcinogens must get inside the body (such as through inhalation) and require years of exposure to produce cancer.

    Physical trauma resulting in cancer is relatively rare.[83] Claims that breaking bones resulted in bone cancer, for example, have not been proven. Similarly, physical trauma is not accepted as a cause for cervical cancer, breast cancer or brain cancer. One accepted source is frequent, long-term application of hot objects to the body. It is possible that repeated burns on the same part of the body, such as those produced by kanger and kairo heaters (charcoal hand warmers), may produce skin cancer, especially if carcinogenic chemicals are also present. Frequent consumption of scalding hot tea may produce esophageal cancer. Generally, it is believed that cancer arises, or a pre-existing cancer is encouraged, during the process of healing, rather than directly by the trauma. However, repeated injuries to the same tissues might promote excessive cell proliferation, which could then increase the odds of a cancerous mutation.

    Chronic inflammation has been hypothesized to directly cause mutation.[84] Inflammation can contribute to proliferation, survival, angiogenesis and migration of cancer cells by influencing the tumor microenvironment.[85] [86] Oncogenes build up an inflammatory pro-tumorigenic microenvironment.[87]

    Hormones

    Hormones also play a role in the development of cancer by promoting cell proliferation.[88] Insulin-like growth factors and their binding proteins play a key role in cancer cell proliferation, differentiation and apoptosis, suggesting possible involvement in carcinogenesis.[89]

    Hormones are important agents in sex-related cancers, such as cancer of the breast, endometrium, prostate, ovary and testis and also of thyroid cancer and bone cancer. For example, the daughters of women who have breast cancer have significantly higher levels of estrogen and progesterone than the daughters of women without breast cancer. These higher hormone levels may explain their higher risk of breast cancer, even in the absence of a breast-cancer gene. Similarly, men of African ancestry have significantly higher levels of testosterone than men of European ancestry and have a correspondingly higher level of prostate cancer. Men of Asian ancestry, with the lowest levels of testosterone-activating androstanediol glucuronide, have the lowest levels of prostate cancer.

    Other factors are relevant: obese people have higher levels of some hormones associated with cancer and a higher rate of those cancers. Women who take hormone replacement therapy have a higher risk of developing cancers associated with those hormones. On the other hand, people who exercise far more than average have lower levels of these hormones and lower risk of cancer. Osteosarcoma may be promoted by growth hormones. Some treatments and prevention approaches leverage this cause by artificially reducing hormone levels and thus discouraging hormone-sensitive cancers.

    Autoimmune diseases

    There is an association between celiac disease and an increased risk of all cancers. People with untreated celiac disease have a higher risk, but this risk decreases with time after diagnosis and strict treatment. This may be due to the adoption of a gluten-free diet, which seems to have a protective role against development of malignancy in people with celiac disease. However, the delay in diagnosis and initiation of a gluten-free diet seems to increase the risk of malignancies.[90] Rates of gastrointestinal cancers are increased in people with Crohn's disease and ulcerative colitis, due to chronic inflammation. Immunomodulators and biologic agents used to treat these diseases may promote developing extra-intestinal malignancies.[91]

    Pathophysiology

    See main article: Carcinogenesis.

    Genetics

    See main article: Oncogenomics. Cancer is fundamentally a disease of tissue growth regulation. For a normal cell to transform into a cancer cell, the genes that regulate cell growth and differentiation must be altered.[92]

    The affected genes are divided into two broad categories. Oncogenes are genes that promote cell growth and reproduction. Tumor suppressor genes are genes that inhibit cell division and survival. Malignant transformation can occur through the formation of novel oncogenes, the inappropriate over-expression of normal oncogenes, or by the under-expression or disabling of tumor suppressor genes. Typically, changes in multiple genes are required to transform a normal cell into a cancer cell.[93]

    Genetic changes can occur at different levels and by different mechanisms. The gain or loss of an entire chromosome can occur through errors in mitosis. More common are mutations, which are changes in the nucleotide sequence of genomic DNA.

    Large-scale mutations involve the deletion or gain of a portion of a chromosome. Genomic amplification occurs when a cell gains copies (often 20 or more) of a small chromosomal locus, usually containing one or more oncogenes and adjacent genetic material. Translocation occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the Philadelphia chromosome, or translocation of chromosomes 9 and 22, which occurs in chronic myelogenous leukemia and results in production of the BCR-abl fusion protein, an oncogenic tyrosine kinase.

    Small-scale mutations include point mutations, deletions, and insertions, which may occur in the promoter region of a gene and affect its expression, or may occur in the gene's coding sequence and alter the function or stability of its protein product. Disruption of a single gene may also result from integration of genomic material from a DNA virus or retrovirus, leading to the expression of viral oncogenes in the affected cell and its descendants.

    Replication of the data contained within the DNA of living cells will probabilistically result in some errors (mutations). Complex error correction and prevention are built into the process and safeguard the cell against cancer. If a significant error occurs, the damaged cell can self-destruct through programmed cell death, termed apoptosis. If the error control processes fail, then the mutations will survive and be passed along to daughter cells.

    Some environments make errors more likely to arise and propagate. Such environments can include the presence of disruptive substances called carcinogens, repeated physical injury, heat, ionising radiation, or hypoxia.[94]

    The errors that cause cancer are self-amplifying and compounding, for example:

    • A mutation in the error-correcting machinery of a cell might cause that cell and its children to accumulate errors more rapidly.
    • A further mutation in an oncogene might cause the cell to reproduce more rapidly and more frequently than its normal counterparts.
    • A further mutation may cause loss of a tumor suppressor gene, disrupting the apoptosis signaling pathway and immortalizing the cell.
    • A further mutation in the signaling machinery of the cell might send error-causing signals to nearby cells.

    The transformation of a normal cell into cancer is akin to a chain reaction caused by initial errors, which compound into more severe errors, each progressively allowing the cell to escape more controls that limit normal tissue growth. This rebellion-like scenario is an undesirable survival of the fittest, where the driving forces of evolution work against the body's design and enforcement of order. Once cancer has begun to develop, this ongoing process, termed clonal evolution, drives progression towards more invasive stages.[95] Clonal evolution leads to intra-tumour heterogeneity (cancer cells with heterogeneous mutations) that complicates designing effective treatment strategies and requires an evolutionary approach to designing treatment.

    Characteristic abilities developed by cancers are divided into categories, specifically evasion of apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative potential, metastasis, reprogramming of energy metabolism and evasion of immune destruction.

    Epigenetics

    See main article: Cancer epigenetics.

    The classical view of cancer is a set of diseases driven by progressive genetic abnormalities that include mutations in tumor-suppressor genes and oncogenes, and in chromosomal abnormalities. A role for epigenetic alterations was identified in the early 21st century.[96]

    Epigenetic alterations are functionally relevant modifications to the genome that do not change the nucleotide sequence. Examples of such modifications are changes in DNA methylation (hypermethylation and hypomethylation), histone modification[97] and changes in chromosomal architecture (caused by inappropriate expression of proteins such as HMGA2 or HMGA1).[98] Each of these alterations regulates gene expression without altering the underlying DNA sequence. These changes may remain through cell divisions, endure for multiple generations, and can be considered as equivalent to mutations.

    Epigenetic alterations occur frequently in cancers. As an example, one study listed protein coding genes that were frequently altered in their methylation in association with colon cancer. These included 147 hypermethylated and 27 hypomethylated genes. Of the hypermethylated genes, 10 were hypermethylated in 100% of colon cancers and many others were hypermethylated in more than 50% of colon cancers.[99]

    While epigenetic alterations are found in cancers, the epigenetic alterations in DNA repair genes, causing reduced expression of DNA repair proteins, may be of particular importance. Such alterations may occur early in progression to cancer and are a possible cause of the genetic instability characteristic of cancers.[100] [101] [102]

    Reduced expression of DNA repair genes disrupts DNA repair. This is shown in the figure at the 4th level from the top. (In the figure, red wording indicates the central role of DNA damage and defects in DNA repair in progression to cancer.) When DNA repair is deficient DNA damage remains in cells at a higher than usual level (5th level) and causes increased frequencies of mutation and/or epimutation (6th level). Mutation rates increase substantially in cells defective in DNA mismatch repair[103] [104] or in homologous recombinational repair (HRR).[105] Chromosomal rearrangements and aneuploidy also increase in HRR defective cells.[106]

    Higher levels of DNA damage cause increased mutation (right side of figure) and increased epimutation. During repair of DNA double strand breaks, or repair of other DNA damage, incompletely cleared repair sites can cause epigenetic gene silencing.[107] [108]

    Deficient expression of DNA repair proteins due to an inherited mutation can increase cancer risks. Individuals with an inherited impairment in any of 34 DNA repair genes (see article DNA repair-deficiency disorder) have increased cancer risk, with some defects ensuring a 100% lifetime chance of cancer (e.g. p53 mutations).[109] Germ line DNA repair mutations are noted on the figure's left side. However, such germline mutations (which cause highly penetrant cancer syndromes) are the cause of only about 1 percent of cancers.[110]

    In sporadic cancers, deficiencies in DNA repair are occasionally caused by a mutation in a DNA repair gene but are much more frequently caused by epigenetic alterations that reduce or silence expression of DNA repair genes. This is indicated in the figure at the 3rd level. Many studies of heavy metal-induced carcinogenesis show that such heavy metals cause a reduction in expression of DNA repair enzymes, some through epigenetic mechanisms. DNA repair inhibition is proposed to be a predominant mechanism in heavy metal-induced carcinogenicity. In addition, frequent epigenetic alterations of the DNA sequences code for small RNAs called microRNAs (or miRNAs). miRNAs do not code for proteins, but can "target" protein-coding genes and reduce their expression.

    Cancers usually arise from an assemblage of mutations and epimutations that confer a selective advantage leading to clonal expansion (see Field defects in progression to cancer). Mutations, however, may not be as frequent in cancers as epigenetic alterations. An average cancer of the breast or colon can have about 60 to 70 protein-altering mutations, of which about three or four may be "driver" mutations and the remaining ones may be "passenger" mutations.[111]

    Metastasis

    See main article: Metastasis. Metastasis is the spread of cancer to other locations in the body. The dispersed tumors are called metastatic tumors, while the original is called the primary tumor. Almost all cancers can metastasize. Most cancer deaths are due to cancer that has metastasized.

    Metastasis is common in the late stages of cancer and it can occur via the blood or the lymphatic system or both. The typical steps in metastasis are local invasion, intravasation into the blood or lymph, circulation through the body, extravasation into the new tissue, proliferation and angiogenesis. Different types of cancers tend to metastasize to particular organs, but overall the most common places for metastases to occur are the lungs, liver, brain and the bones.

    Metabolism

    See main article: Tumor metabolome.

    Normal cells typically generate only about 30% of energy from glycolysis,[112] whereas most cancers rely on glycolysis for energy production (Warburg effect).[113] [114] But a minority of cancer types rely on oxidative phosphorylation as the primary energy source, including lymphoma, leukemia, and endometrial cancer.[115] Even in these cases, however, the use of glycolysis as an energy source rarely exceeds 60%. A few cancers use glutamine as the major energy source, partly because it provides nitrogen required for nucleotide (DNA, RNA) synthesis.[116] Cancer stem cells often use oxidative phosphorylation or glutamine as a primary energy source.[117]

    Diagnosis

    Most cancers are initially recognized either because of the appearance of signs or symptoms or through screening.[118] Neither of these leads to a definitive diagnosis, which requires the examination of a tissue sample by a pathologist.[119] People with suspected cancer are investigated with medical tests. These commonly include blood tests, X-rays, (contrast) CT scans and endoscopy.

    The tissue diagnosis from the biopsy indicates the type of cell that is proliferating, its histological grade, genetic abnormalities and other features. Together, this information is useful to evaluate the prognosis and to choose the best treatment.

    Cytogenetics and immunohistochemistry are other types of tissue tests. These tests provide information about molecular changes (such as mutations, fusion genes and numerical chromosome changes) and may thus also indicate the prognosis and best treatment.

    Cancer diagnosis can cause psychological distress and psychosocial interventions, such as talking therapy, may help people with this.[120] Some people choose to disclose the diagnosis widely; others prefer to keep the information private, especially shortly after the diagnosis, or to disclose it only partially or to selected people.[121]

    Classification

    Cancers are classified by the type of cell that the tumor cells resemble and is therefore presumed to be the origin of the tumor. These types include:

    Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or tissue of origin as the root. For example, cancers of the liver parenchyma arising from malignant epithelial cells is called hepatocarcinoma, while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma and a cancer arising from fat cells is called a liposarcoma. For some common cancers, the English organ name is used. For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers to the appearance of cancer under the microscope, which suggests that it has originated in the milk ducts.

    Benign tumors (which are not cancers) are named using -oma as a suffix with the organ name as the root. For example, a benign tumor of smooth muscle cells is called a leiomyoma (the common name of this frequently occurring benign tumor in the uterus is fibroid). Confusingly, some types of cancer use the -noma suffix, examples including melanoma and seminoma.

    Some types of cancer are named for the size and shape of the cells under a microscope, such as giant cell carcinoma, spindle cell carcinoma and small-cell carcinoma.

    . Pathology Outlines.
  124. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJ . 19823935 . American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity . CA: A Cancer Journal for Clinicians . 56 . 5 . 254–81; quiz 313–14 . 2006 . 17005596 . 10.3322/canjclin.56.5.254. free /> In the United States, excess body weight is associated with the development of many types of cancer and is a factor in 14–20% of cancer deaths. A UK study including data on over 5 million people showed higher body mass index to be related to at least 10 types of cancer and responsible for around 12,000 cases each year in that country.[59] .